{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T02:03:45Z","timestamp":1784253825433,"version":"3.55.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-026-05024-9","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T01:15:45Z","timestamp":1784250945000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Diagnostic performance of fecal eosinophil-derived neurotoxin and lipocalin-2 in pediatric inflammatory bowel disease"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3077-8265","authenticated-orcid":false,"given":"Ragaey Ahmad","family":"Eid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada Atteya","family":"Fakhry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doaa Mabrouk","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Hodeib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"5024_CR1","doi-asserted-by":"publisher","unstructured":"Geboes K, Dewit O, Moreels TG, Faa G, Jouret-Mourin A. Inflammatory bowel diseases. In: Colitis: a Practical Approach to Colon and Ileum Biopsy Interpretation. Cham: Springer International Publishing; 2018. p. 107\u201340. https:\/\/doi.org\/10.1007\/978-3-319-89503-1_8.","DOI":"10.1007\/978-3-319-89503-1_8"},{"issue":"1","key":"5024_CR2","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/ibd\/izae047","volume":"31","author":"LR J\u00f8lving","year":"2025","unstructured":"J\u00f8lving LR, Zegers FD, Lund K, Wod M, Nielsen J, Qvist N, Nielsen RG, N\u00f8rg\u00e5rd BM. Children and adolescents diagnosed with inflammatory bowel disease are at increased risk of developing diseases with a possible autoimmune pathogenesis. Inflamm Bowel Dis. 2025;31(1):87\u201394.","journal-title":"Inflamm Bowel Dis"},{"key":"5024_CR3","doi-asserted-by":"publisher","unstructured":"Wanas H, Mekawy DM, Raafat Hamed RM, Eid RA, Abd Elmaogod EA, Musa ENA, et al. Anti-inflammatory effect of pirfenidone compared to dexamethasone in ulcerative colitis model induced by acetic acid in rats: involvement of miR-146a and TLR4\/NF-\u03baB signaling. Naunyn Schmiedebergs Arch Pharmacol. 2026;399(2):2871\u201386. https:\/\/doi.org\/10.1007\/s00210-025-04571-4.","DOI":"10.1007\/s00210-025-04571-4"},{"issue":"2","key":"5024_CR4","first-page":"134","volume":"2","author":"MDM Prata","year":"2016","unstructured":"Prata MDM, Havt A, Bolick DT, Pinkerton R, Lima AAM, Guerrant RL. Comparisons between myeloperoxidase, lactoferrin, calprotectin and lipocalin-2, as fecal biomarkers of intestinal inflammation in malnourished children. J Transl Sci. 2016;2(2):134.","journal-title":"J Transl Sci"},{"issue":"1","key":"5024_CR5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1093\/ecco-jcc\/jjaa124","volume":"15","author":"A Zollner","year":"2021","unstructured":"Zollner A, Schmiderer A, Reider SJ, Oberhuber G, Pfister A, Texler B, et al. Faecal biomarkers in inflammatory bowel diseases: calprotectin versus lipocalin-2\u2014a comparative study. J Crohn\u2019s Colitis. 2021;15(1):43\u201354.","journal-title":"J Crohn\u2019s Colitis"},{"issue":"8","key":"5024_CR6","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.3390\/jcm10081595","volume":"10","author":"M Roca","year":"2021","unstructured":"Roca M, Rodriguez Varela A, Carvajal E, Donat E, Cano F, Armisen A, et al. Fecal calprotectin and eosinophil-derived neurotoxin in children with non-IgE-mediated cow\u2019s milk protein allergy. J Clin Med. 2021;10(8):1595.","journal-title":"J Clin Med"},{"issue":"7","key":"5024_CR7","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.3390\/biomedicines10071492","volume":"10","author":"Z Alghoul","year":"2022","unstructured":"Alghoul Z, Yang C, Merlin D. The current status of molecular biomarkers for inflammatory bowel disease. Biomedicines. 2022;10(7):1492.","journal-title":"Biomedicines"},{"issue":"4","key":"5024_CR8","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.cgh.2020.12.017","volume":"20","author":"R Khanna","year":"2022","unstructured":"Khanna R, Ma C, Jairath V, Casteele NV, Zou G, Feagan BG. Endoscopic assessment of inflammatory bowel disease activity in clinical trials. Clin Gastroenterol Hepatol. 2022;20(4):727\u201336.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5024_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1046\/j.1365-2036.17.s2.17.x","volume":"17","author":"R Sostegni","year":"2003","unstructured":"Sostegni R, Daperno M, Scaglione N, Lavagna A, Rocca R, Pera A. Crohn\u2019s disease: monitoring disease activity. Aliment Pharmacol Ther. 2003;17:11\u20137.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"5024_CR10","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1097\/MPG.0000000000003046","volume":"72","author":"CR Koninckx","year":"2021","unstructured":"Koninckx CR, Donat E, Benninga MA, Broekaert IJ, Gottrand F, Kolho KL, et al. The use of fecal calprotectin testing in paediatric disorders: a position paper of the European Society for Paediatric Gastroenterology and Nutrition Gastroenterology Committee. J Pediatr Gastroenterol Nutr. 2021;72(4):617\u201340.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"11","key":"5024_CR11","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1002\/ibd.22863","volume":"18","author":"P Molander","year":"2012","unstructured":"Molander P, af Bj\u00f6rkesten CG, Mustonen H, Haapam\u00e4ki J, Vauhkonen M, Kolho KL, et al. Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNF\u03b1 blocking agents. Inflamm Bowel Dis. 2012;18(11):2011\u20137.","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"5024_CR12","first-page":"247","volume":"82","author":"JV Arcos-Machancoses","year":"2015","unstructured":"Arcos-Machancoses JV, Donat-Aliaga E, Polo-Miquel B, Masip-Sim\u00f3 E, Ribes-Koninckx C, Pereda-P\u00e9rez A. Description and study of risk factors for the diagnostic delay of paediatric inflammatory bowel disease. Pediatr (Engl Ed). 2015;82(4):247\u201354.","journal-title":"Pediatr (Engl Ed)"},{"issue":"6","key":"5024_CR13","doi-asserted-by":"publisher","first-page":"921","DOI":"10.5009\/gnl210488","volume":"16","author":"S Park","year":"2022","unstructured":"Park S, Kang B, Kim S, Choi S, Suh HR, Kim ES, et al. Comparison between pediatric Crohn\u2019s disease and ulcerative colitis at diagnosis in Korea: results from a multicenter, registry-based, inception cohort study. Gut Liver. 2022;16(6):921.","journal-title":"Gut Liver"},{"issue":"1","key":"5024_CR14","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.crohns.2012.05.024","volume":"7","author":"C Jakobsen","year":"2013","unstructured":"Jakobsen C, Paerregaard A, Munkholm P, Wewer V. Environmental factors and risk of developing paediatric inflammatory bowel disease\u2014a population-based study 2007\u20132009. J Crohn\u2019s Colitis. 2013;7(1):79\u201388.","journal-title":"J Crohn\u2019s Colitis"},{"key":"5024_CR15","doi-asserted-by":"publisher","unstructured":"Agrawal M, Sabino J, Frias-Gomes C, Hillenbrand CM, Soudant C, Axelrad JE, et al. Early life exposures and the risk of inflammatory bowel disease: systematic review and meta-analyses. EClinicalMedicine. 2021;36:100884. https:\/\/doi.org\/10.1016\/j.eclinm.2021.100884.","DOI":"10.1016\/j.eclinm.2021.100884"},{"issue":"5","key":"5024_CR16","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/ibd.21805","volume":"18","author":"P Bager","year":"2012","unstructured":"Bager P, Simonsen J, Nielsen NM, Frisch M. Cesarean section and offspring\u2019s risk of inflammatory bowel disease: a national cohort study. Inflamm Bowel Dis. 2012;18(5):857\u201362.","journal-title":"Inflamm Bowel Dis"},{"issue":"24","key":"5024_CR17","doi-asserted-by":"publisher","first-page":"5103","DOI":"10.3390\/nu15245103","volume":"15","author":"B Bertin","year":"2023","unstructured":"Bertin B, Foligne B, Ley D, Lesage J, Beghin L, Morcel J, et al. An overview of the influence of breastfeeding on the development of inflammatory bowel disease. Nutrients. 2023;15(24):5103.","journal-title":"Nutrients"},{"key":"5024_CR18","doi-asserted-by":"publisher","first-page":"200096","DOI":"10.1016\/j.jpedcp.2024.200096","volume":"12","author":"S Andersen","year":"2024","unstructured":"Andersen S, Hestetun SV, Bernklev T, Perminow G, St\u00f8rdal K. Fetal and early-life antibiotics and risk of pediatric inflammatory bowel disease: a population-based nationwide register study. J Pediatr Clin Pract. 2024;12:200096.","journal-title":"J Pediatr Clin Pract"},{"issue":"12","key":"5024_CR19","doi-asserted-by":"publisher","first-page":"3513","DOI":"10.1111\/j.1572-0241.1999.01640.x","volume":"94","author":"O Saitoh","year":"1999","unstructured":"Saitoh O, Kojima K, Sugi K, Matsuse R, Uchida K, Tabata K, et al. Fecal eosinophil granule-derived proteins reflect disease activity in inflammatory bowel disease. Am J Gastroenterol. 1999;94(12):3513\u201320.","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"5024_CR20","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1111\/j.1572-0241.2002.05837.x","volume":"97","author":"CG Peterson","year":"2002","unstructured":"Peterson CG, Eklund E, Taha Y, Raab Y, Carlson M. A new method for the quantification of neutrophil and eosinophil cationic proteins in feces: establishment of normal levels and clinical application in patients with inflammatory bowel disease. Am J Gastroenterol. 2002;97(7):1755\u201362.","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"5024_CR21","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1177\/0192623316665927","volume":"44","author":"H Hsieh","year":"2016","unstructured":"Hsieh H, Morin J, Filliettaz C, Varada R, LaBarre S, Radi Z. Fecal lipocalin-2 as a sensitive and noninvasive biomarker in the TNBS Crohn\u2019s inflammatory bowel disease model. Toxicol Pathol. 2016;44(8):1084\u201394.","journal-title":"Toxicol Pathol"},{"key":"5024_CR22","doi-asserted-by":"publisher","unstructured":"Kardas Yildiz A, Urganci N, Usta AM. Evaluation of fecal neutrophil gelatinase-associated lipocalin levels in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2025;80(5):792\u20138. https:\/\/doi.org\/10.1002\/jpn3.70015.","DOI":"10.1002\/jpn3.70015"},{"issue":"1","key":"5024_CR23","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/jgh.13598","volume":"32","author":"S Thorsvik","year":"2017","unstructured":"Thorsvik S, Dam\u00e5s JK, Granlund AV, Flo TH, Bergh K, \u00d8stvik AE, et al. Fecal neutrophil gelatinase-associated lipocalin as a biomarker for inflammatory bowel disease. J Gastroenterol Hepatol. 2017;32(1):128\u201335.","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"5024_CR24","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41390-021-01680-7","volume":"91","author":"MP Thibault","year":"2022","unstructured":"Thibault MP, Tremblay \u00c9, Horth C, Fournier-Morin A, Grynspan D, Babakissa C, et al. Lipocalin-2 and calprotectin as stool biomarkers for predicting necrotizing enterocolitis in premature neonates. Pediatr Res. 2022;91(1):129\u201336.","journal-title":"Pediatr Res"},{"issue":"7","key":"5024_CR25","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3109\/00365521.2016.1141432","volume":"51","author":"M Wagner","year":"2016","unstructured":"Wagner M, Sj\u00f6berg K, Vigren L, Olesen M, Benoni C, Toth E, et al. Elevated fecal levels of eosinophil granule proteins predict collagenous colitis in patients referred to colonoscopy due to chronic non-bloody diarrhea. Scand J Gastroenterol. 2016;51(7):835\u201341.","journal-title":"Scand J Gastroenterol"},{"key":"5024_CR26","doi-asserted-by":"publisher","first-page":"793760","DOI":"10.3389\/fonc.2021.793760","volume":"11","author":"F Kou","year":"2022","unstructured":"Kou F, Cheng Y, Shi L, Liu J, Liu Y, Shi R, et al. LCN2 as a potential diagnostic biomarker for ulcerative colitis-associated carcinogenesis related to disease duration. Front Oncol. 2022;11:793760.","journal-title":"Front Oncol"},{"issue":"9","key":"5024_CR27","doi-asserted-by":"publisher","first-page":"e44328","DOI":"10.1371\/journal.pone.0044328","volume":"7","author":"B Chassaing","year":"2012","unstructured":"Chassaing B, Srinivasan G, Delgado MA, Young AN, Gewirtz AT, Vijay-Kumar M. Fecal lipocalin 2, a sensitive and broadly dynamic non-invasive biomarker for intestinal inflammation. PLoS ONE. 2012;7(9):e44328.","journal-title":"PLoS ONE"},{"key":"5024_CR28","doi-asserted-by":"publisher","first-page":"1015372","DOI":"10.3389\/fimmu.2022.1015372","volume":"13","author":"SK Yadav","year":"2022","unstructured":"Yadav SK, Ito N, Mindur JE, Kumar H, Youssef M, Suresh S, et al. Fecal Lcn-2 level is a sensitive biological indicator for gut dysbiosis and intestinal inflammation in multiple sclerosis. Front Immunol. 2022;13:1015372.","journal-title":"Front Immunol"},{"issue":"4","key":"5024_CR29","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1097\/MPG.0000000000001542","volume":"65","author":"M Roca","year":"2017","unstructured":"Roca M, Varela AR, Donat E, Cano F, Hervas D, Armisen A, et al. Fecal calprotectin and eosinophil-derived neurotoxin in healthy children between 0 and 12 years. J Pediatr Gastroenterol Nutr. 2017;65(4):394\u20138.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"36","key":"5024_CR30","doi-asserted-by":"publisher","first-page":"5584","DOI":"10.3748\/wjg.14.5584","volume":"14","author":"M Wagner","year":"2008","unstructured":"Wagner M, Peterson CG, Ridefelt P, Sangfelt P, Carlson M. Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease. World J Gastroenterol. 2008;14(36):5584\u20139.","journal-title":"World J Gastroenterol"},{"issue":"10","key":"5024_CR31","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1080\/00365521.2019.1670251","volume":"54","author":"K Amcoff","year":"2019","unstructured":"Amcoff K, Cao Y, Zhulina Y, Lampinen M, Halfvarson J, Carlson M. Prognostic significance of faecal eosinophil granule proteins in inflammatory bowel disease. Scand J Gastroenterol. 2019;54(10):1237\u201344.","journal-title":"Scand J Gastroenterol"},{"issue":"8","key":"5024_CR32","first-page":"e00469","volume":"13","author":"H Ekoff","year":"2022","unstructured":"Ekoff H, Rydell N, Hellstr\u00f6m PM, Mov\u00e9rare R. Fecal and serum granulocyte protein levels in inflammatory bowel disease and irritable bowel syndrome and their relation to disease activity. Clin Transl Gastroenterol. 2022;13(8):e00469.","journal-title":"Clin Transl Gastroenterol"},{"issue":"8","key":"5024_CR33","doi-asserted-by":"publisher","first-page":"e00605","DOI":"10.14309\/ctg.0000000000000605","volume":"14","author":"ML Lundstr\u00f6m","year":"2023","unstructured":"Lundstr\u00f6m ML, Peterson C, Lampinen M, Hedin CR, Keita \u00c5V, Kruse R, et al. Fecal biomarkers of neutrophil and eosinophil origin reflect the response to biological therapy and corticosteroids in patients with inflammatory bowel disease. Clin Transl Gastroenterol. 2023;14(8):e00605.","journal-title":"Clin Transl Gastroenterol"},{"key":"5024_CR34","doi-asserted-by":"publisher","unstructured":"Khattab RARM, Samy HAH, El Sayed AH, Ali Assem AA, Mansour MSM. Correlation between fecal (calprotectin and lactoferrin) results and colonoscopic findings in chronic diarrhea and recurrent abdominal pain in children and adolescents. Int J Health Sci. 2022;6(S1):8229\u201343. https:\/\/doi.org\/10.53730\/ijhs.v6nS1.6782.","DOI":"10.53730\/ijhs.v6nS1.6782"},{"issue":"4","key":"5024_CR35","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1111\/j.1572-0241.2007.01126.x","volume":"102","author":"AC Von Roon","year":"2007","unstructured":"Von Roon AC, Karamountzos L, Purkayastha S, Reese GE, Darzi AW, Teare JP, et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol. 2007;102(4):803\u201313.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"5024_CR36","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s43162-023-00263-8","volume":"35","author":"RSR Sarhan","year":"2023","unstructured":"Sarhan RSR, Marei YM, Marei YM. Evaluation of the diagnostic performance of estimated fecal calprotectin and serum intelectin-1 and C-reactive protein solo or in combination for differentiation between patients with query ulcerative colitis and irritable bowel syndrome. Egypt J Intern Med. 2023;35(1):79.","journal-title":"Egypt J Intern Med"},{"issue":"10","key":"5024_CR37","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.3390\/jcm9103147","volume":"9","author":"A Rycyk","year":"2020","unstructured":"Rycyk A, Cudowska B, Lebensztejn DM. Eosinophil-derived neurotoxin, tumor necrosis factor alpha, and calprotectin as non-invasive biomarkers of food protein-induced allergic proctocolitis in infants. J Clin Med. 2020;9(10):3147.","journal-title":"J Clin Med"},{"issue":"4","key":"5024_CR38","first-page":"435","volume":"11","author":"F Magro","year":"2017","unstructured":"Magro F, Lopes S, Coelho R, Cotter J, Dias de Castro F, Tavares de Sousa H, et al. Accuracy of faecal calprotectin and neutrophil gelatinase B-associated lipocalin in evaluating subclinical inflammation in UlceRaTIVE colitis\u2014the ACERTIVE study. J Crohn\u2019s Colitis. 2017;11(4):435\u201344.","journal-title":"J Crohn\u2019s Colitis"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-05024-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-05024-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-05024-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T01:34:51Z","timestamp":1784252091000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-026-05024-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5024"],"URL":"https:\/\/doi.org\/10.1186\/s12876-026-05024-9","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"22 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by the Ethical Committee of Beni-Suef University Hospital and conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants prior to enrollment. with approval number FMBSUREC\/02012024\/Fakhry, granted on 2nd of January 2024.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"455"}}